Cited by 373Pharmaceutical studies and practicesStatistical Methods in Clinical TrialsPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.

Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation

Open access

EFPIA MID3 Workgroup, Marshall, SF, Burghaus, R, Cosson, V, Cheung, SYA, Chenel, M, DellaPasqua, O, Frey, N, Hamrén, B, Harnisch, L, Ivanow, F, Kerbusch, T, Lippert, J, Milligan, PA, Rohou, S, Staab, A, Steimer, JL, Tornøe, C, Visser, SAG·2016·CPT: Pharmacometrics & Systems Pharmacology

DOI 10.1002/psp4.12049PMC PMC4809625

Open this paper in CoChat — free account Open PDF

Abstract

This document was developed to enable greater consistency in the practice, application, and documentation of Model‐Informed Drug Discovery and Development (MID3) across the pharmaceutical industry. A collection of “good practice” recommendations are assembled here in order to minimize the heterogeneity in both the quality and content of MID3 implementation and documentation. The three major objectives of this white paper are to: i) inform company decision makers how the strategic integration of MID3 can benefit R&D efficiency; ii) provide MID3 analysts with sufficient material to enhance the planning, rigor, and consistency of the application of MID3; and iii) provide regulatory authorities with substrate to develop MID3 related and/or MID3 enabled guidelines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/psp4.12049

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Bergstrand, M., Hooker, A. C., Wallin, J. E., & Karlsson, M. O. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9255-z · Cited by 1,435
Ways to Fit a PK Model with Some Data Below the Quantification Limit
Beal, S. L. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1012299115260 · Cited by 1,156
Understanding the Dose-Effect Relationship
Holford, N. H. G., & Sheiner, L. B. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106060-00002 · Cited by 1,147
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
Caro, J., Briggs, A., Siebert, U., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.012 · Cited by 1,006
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods
Mould, D., & Upton, R. N. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.14 · Cited by 906
Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
Savić, R. M., & Karlsson, M. O. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9133-0 · Cited by 641
Learning versus confirming in clinical drug development*
Sheiner, L. B. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90160-0 · Cited by 633
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development
Mould, D., & Upton, R. N. (2012) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.4 · Cited by 589
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
Sager, J. E., Yu, J., Ragueneau, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 541

Flagged first, then by citations

Show all 82 references

1 of the 82 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

EMA/EFPIA M&S workshop 2011.http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2011/07/event_detail_000440.jsp&mid=WC0b01ac058004d5c3(2011).
EMA/EFPIAEuropean Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop on the importance of dose finding and dose selection for the successful development licensing and lifecycle management of medicinal products.http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2014/06/event_detail_000993.jsp&mid=WC0b01ac058004d5c3(2014).
Holford N.H.G., 2006, Principles of Clinical Pharmacology 2nd edn, 369
Meibohm B., 1997, Basic concept of PK/PD modeling, Int. J. Clin. Pharmacol. Ther., 35, 401
10.1038/clpt.2012.53 · DOI
Goggin T., 2003, Simulation for designing clinical trials, 227

Sorted by citations

Items 201–300 of 372

Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics
Derbalah, A., Stader, F., Liu, C., Żyła, A., Abdulla, T., Wu, Q., Jamei, M., Gardner, I., & Sepp, A. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-09980-9 · Cited by 5
From reactive to predictive: Advancing biologic dosing in dermatology
Eylenbosch, A., Wei, R., Soenen, R., Smith, C. H., Standing, J. F., Mahil, S. K., & Lambert, J. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70147 · Cited by 5
Integration of Clinical Pharmacokinetic Database With Compartmental Modeling and Regulatory Data Analysis
Agboola, O. E., Agboola, S. S., Shaleye, A. B., Umoekam, A. S., Ayinla, Z. A., & Olasehinde, T. Y. (2026) · Current Therapeutic Research · doi:10.1016/j.curtheres.2026.100832 · Cited by 5
From Plan to Pivot: How Model‐Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials
Mercier, A., Ueckert, S., Sunnåker, M., Hamrén, B., Ambery, P., Greasley, P. J., & Åstrand, M. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3362 · Cited by 5
Self-citation
How debunking biases in research and development decisions could lead to more equitable healthcare?
Weber, B., Zineh, I., Lalonde, R., & Visser, S. A. G. (2024) · Clinical and Translational Science · doi:10.1111/cts.13880 · Cited by 5
Self-citation
Selection and prioritization of candidate combination regimens for the treatment of tuberculosis
Strydom, N., van Wijk, R. C., Wang, Q., Ernest, J. P., Chaba, L., Li, Z., Nuermberger, E. L., & Savić, R. M. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adi4000 · Cited by 5
In Vitro–In Silico Modeling of Caffeine and Diclofenac Permeation in Static and Fluidic Systems with a 16HBE Lung Cell Barrier
Kovar, L., Wien, L., Selzer, D., Kohl, Y., Bals, R., & Lehr, T. (2022) · Pharmaceuticals · doi:10.3390/ph15020250 · Cited by 3
Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins and Nucleic Acids
Meibohm, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_6 · Cited by 5
Innovative research methodologies in the EU regulatory framework: an analysis of EMA qualification procedures from a pediatric perspective
Giannuzzi, V., Bertolani, A., Torretta, S., Reggiardo, G., Toich, E., Bonifazi, D., & Ceci, A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1369547 · Cited by 5
Population kinetic/pharmacodynamic modelling of the haemodynamic effects of cafedrine/theodrenaline (Akrinor) under general anaesthesia
Dings, C., Lehr, T., Vojnar, B., Gaik, C., Koch, T., Eberhart, L. H. J., Huljic‐Lankinen, S., Murst, M., & Kreuer, S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16083 · Cited by 5
Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials
Saito, R., & Nakada, T. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101019 · Cited by 5
Application of MIDD to accelerate the development of anti-infectives: Current status and future perspectives
Mak, W. Y., He, Q., Yang, W., Xu, N., Zheng, A., Chen, M., Lin, J., Shi, Y., Xiang, X., & Zhu, X. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115447 · Cited by 5
Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments
Chasseloup, E., Tessier, A., & Karlsson, M. O. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00596-8 · Cited by 5
Accelerating Digitalization in Healthcare with the InSilicoTrials Cloud-Based Platform: Four Use Cases
Nicolò, C., Sips, F. L. P., Vaghi, C., Baretta, A., Carbone, V., Emili, L., & Bursi, R. (2022) · Annals of Biomedical Engineering · doi:10.1007/s10439-022-03052-6 · Cited by 5
Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver
Asano, D., Nakamura, K., Nishiya, Y., Shiozawa, H., Takakusa, H., Shibayama, T., Inoue, S., Shinozuka, T., Hamada, T., Yahara, C., et al. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.001000 · Cited by 5
Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling
Hügl, B. J., Horlitz, M., Fischer, K., & Kreutz, R. H. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead004 · Cited by 5
A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor
Song, L., Wang, X., Sun, J., Hu, X., Li, H., Hu, P., & Liu, D. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01209-z · Cited by 5
Data-intensive drug development in the information age: applications of Systems Biology/Pharmacology/Toxicology
Kiyosawa, N., & Manabe, S. (2016) · The Journal of Toxicological Sciences · doi:10.2131/jts.41.sp15 · Cited by 5
Development and performance of npde for the evaluation of time-to-event models
Cerou, M., Lavielle, M., Brendel, K., Chenel, M., & Comets, E. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2291-3 · Cited by 5
Self-citation
A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation
Cheung, S. Y. A., PARKINSON, J. R., Hamrén, U. W., Dota, C., Kragh, A. M., Bergenholm, L., Vik, T., Collins, T. A., Arfvidsson, C., Pollard, C. E., et al. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9589-6 · Cited by 5
Self-citation
Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development
Singh, A. P., & Shah, D. K. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9_4 · Cited by 5
Time to Expect More From Pharmacometrics
Barrett, J. S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1914 · Cited by 5
Pharmacometrics: A Quantitative Decision-Making Tool in Drug Development
Xu, Y. C., & Kimko, H. H. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-48555-9_2 · Cited by 5
A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy
Nukala, U., Messan, M. R., Yogurtcu, O. N., Wang, X., & Yang, H. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2101.05359 · Cited by 5
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
Minichmayr, I. K., Karlsson, M. O., & Jönsson, S. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03024-w · Cited by 5
Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products
Selen, A., Müllertz, A., Kesisoglou, F., Ho, R. J. Y., Cook, J., Dickinson, P. A., & Flanagan, T. R. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00534-0 · Cited by 5
Generative Molecular Design and Experimental Validation of Selective Histamine H1 InhibitorsPreprint
McLoughlin, K., Shi, D., Mast, J. E., Bucci, J., Williams, J. P., Jones, W. D., Miyao, D., Nam, L., Osswald, H. L., Zegel'man, L. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.14.528391 · Cited by 6
Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities
Lee, N., Rhee, S., Koo, S. M., Kim, S. W., Lee, G. E., Yie, Y. A., & Kim, Y. (2025) · Clinical and Translational Science · doi:10.1111/cts.70125 · Cited by 4
Repositioning Natural Products in Modern Drug Discovery: Technological Innovation, Systems Pharmacology, and Pathological Validation
Nakadate, K., Ito, N., & Kawakami, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104330 · Cited by 4
A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes
Johnston, C., Eudy‐Byrne, R. J., Elmokadem, A., Nock, V., Marquard, J., Soleymanlou, N., Riggs, M. M., & Liesenfeld, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040485 · Cited by 4
The Impact of Document Management Using Good Practices: A Literature Review
Cumpa, C. A. O., Bendezú, A. E. R., & Jiménez, H. J. B. (2023) · International Journal of Professional Business Review · doi:10.26668/businessreview/2023.v8i11.4112 · Cited by 4
The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making
Starling, S., Kehoe, L. S., Burnett, B. K., Green, P., Venkatakrishnan, K., & Madabushi, R. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3467 · Cited by 5
Template-driven Best Practice Documentation
Alwazae, M. M. S., Perjons, E., & Johannesson, P. (2019) · Knowledge Management Research & Practice · doi:10.1080/14778238.2019.1678411 · Cited by 4
The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia
Michelet, R., Ursino, M., Boulet, S., Franck, S., Casilag, F., Baldry, M., Rolff, J., van Dyk, M., Wicha, S. G., Sirard, J., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050601 · Cited by 4
A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment
Yates, J. W. T., & Cheung, S. Y. A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.027 · Cited by 4
Self-citation
Clozapine-loaded nanocapsules improve antipsychotic activity in rats: building a sequential PopPK/PD model to discriminate nanocarriers in the preformulation step
Ribeiro, A. C. F., Maciel, T. R., Lunardi, A. G., Gomes, D. B., Ibarra, M., & Haas, S. E. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03551-8 · Cited by 4
Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers
Goyal, V., Krantz, E., Simon, F., Neven, A., Eriksson, J., Saayman, A., Lassout, N. I. Z., Louis, M., Robinson, S., Deshmukh, A., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13756 · Cited by 4
Self-citation
Application of Computational Methods for the Safety Assessment of Food Ingredients
Volarath, P., Zang, Y., & Kabadi, S. V. (2019) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-030-16443-0_12 · Cited by 4
Evaluation of Assumptions Underpinning Pharmacometric Models
Ooi, Q. X., Wright, D. F. B., Isbister, G. K., & Duffull, S. B. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0366-2 · Cited by 4
Regulatory Considerations for Building an In Silico Clinical Pharmacology Backbone by 2030
Manolis, E., Musuamba, F. T., & Karlsson, K. E. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1772 · Cited by 4
A Pharmacometrics‐Informed Trial Simulation Framework for Optimizing Study Designs for Disease‐Modifying Treatments in Rare Neurological Disorders
Ryeznik, Y. V., Hilgers, R.-D., Heussen, N. M., Comets, E., Mentré, F., Hendrickx, N., Karlsson, M. O., Hooker, A. C., Hamdan, A., Chen, X., et al. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70082 · Cited by 3
Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca’s collaborative partnerships
Pichardo‐Almarza, C., & Kimko, H. H. C. (2025) · Frontiers in Systems Biology · doi:10.3389/fsysb.2025.1627214 · Cited by 3
Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology
Yates, J. W. T., & Mistry, H. B. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13020 · Cited by 3
MIDD in Japan– Implementations, challenges and opportunities
Hasegawa, M., & Kijima, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115553 · Cited by 3
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig ( EMB ‐02) in Patients With Advanced Solid Tumors
Jiang, C., Ren, F., Zhang, M., Lu, Q., Zeng, S., Yang, G., & Zhu, Y. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70011 · Cited by 3
A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime
O’Jeanson, A., Nielsen, E. I., & Friberg, L. E. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf036 · Cited by 3
Population pharmacokinetic and exposure-response study of a novel anti-tuberculosis drug to inform its dosage design in phase III clinical trial
Kong, W., Liang, H., Zhang, Y., Li, L., Li, Y., Yan, X., & Liu, D. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107160 · Cited by 3
Pharmacokinetic insights of onradivir in influenza treatment to inform pediatric dosing selection in clinical trial
Li, H., Wang, K., Sun, Z., Li, Y., Liu, L., Yang, Y., Chen, X., & Huang, J. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100171 · Cited by 3
Proceedings of a Workshop: US Food and Drug Administration‐International Society of Pharmacometrics Model‐Informed Drug Development in Oncology
Bruno, R., Jin, J. Y., Maxfield, K., Milligan, L., Liu, C., Wang, Y., McKee, A. E., & Zineh, I. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1421 · Cited by 3
An introduction to QSP modeling for pharmacologists
Sayama, H., Nagasaka, Y., & Tabata, K. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.154.143 · Cited by 3
Application of the Nested Enzyme‐Within‐Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects
Takita, H., Darwich, A. S., Ahmad, A., & Rostami‐Hodjegan, A. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12557 · Cited by 3
Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation
Wang, H., Wang, T., Hu, X., Deng, C., Jiang, J., Qin, H., Dong, K., Chen, D., Jin, C., Zhao, Q., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15342 · Cited by 3
Driving Efficiency: Leveraging Model‐Informed Approaches in 505(b)(2) Regulatory Actions
Sharma, V. D., Bhattaram, V. A., Krudys, K. M., Li, Z., Marathe, A., Mehrotra, N., Wang, X., Liu, J., Stier, E. M., Florian, J. A., et al. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6109 · Cited by 3
The Risk of Treating Populations Instead of Patients
Deitchman, A. N. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12402 · Cited by 3
A latent variable approach to account for correlated inputs in global sensitivity analysis
Melillo, N., & Darwich, A. S. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09764-x · Cited by 3
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease
Hoefman, S., Snelder, N., van Noort, M., García-Hernández, A., Onkels, H., Larsson, T. E., & Bergmann, K. R. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09716-x · Cited by 3
Mechanistic modelling of enzyme‐restoration effects of new recombinant liver‐targeted proteins in acute intermittent porphyria
Vera‐Yunca, D., Córdoba, K. M., Parra-Guillen, Z. P., Jericó, D., Fontanellas, A., & Trocóniz, I. F. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15821 · Cited by 2
Integrated pharmacokinetic-pharmacodynamic and agent-based modelling in drug development: Current status and future perspectives
Yates, J. W. T. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115474 · Cited by 2
Integrating Quantitative Methods & Modeling and Analytical Techniques in Reverse Engineering; A Cutting-Edge Strategy in Complex Generic Development
Rajput, A., Pillai, M. S., Ajabiya, J., & Sengupta, P. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03067-x · Cited by 2
Development and evaluation of a model characterizing the release characteristics of a new letrozole long-acting injectable formulation
Pardines, A. C., Ginés, G. L., García-Orueta, G., & Trocóniz, I. F. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107103 · Cited by 2
Population Modelling
Patil, D., Sahoo, J., Pai, R. V., & G., S. N. K. R. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_4 · Cited by 2
Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria
Bienczak, A., Gautier, A., Hua, E., Ji, Y., Scosyrev, E., Smeets, S. J., Severin, T. M., Drollmann, A., Patekar, M., & Savelieva, M. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70098 · Cited by 2
Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia
Mahar, K. M., Yang, S., Johnson, B. M., Visser, S. A. G., van den Berg, P., van Noort, M., & Post, T. M. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70094 · Cited by 2
Self-citation
Pumas: A Unified Platform for Pharmaceutical Modeling and Simulation
Mogensen, P. K., Noack, A., Tarek, M., Elrod, C., Müller‐Widmann, D., Krumbiegel, J., Hatherly, M., Korsbo, N., Rackauckas, C., & Ivaturi, V. D. (2026) · Quantitative Medicine · doi:10.70534/qm-2026-0011 · Cited by 2
Estimation of mechanism-of-action of pharmaceutical compounds based on quantitative systems pharmacology
Saito, R. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.153.124 · Cited by 2
A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory
Carlo, A. D., Tosca, E. M., Melillo, N., & Magni, P. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09872-w · Cited by 2
Improving pharmacometrics analysis efficiency using DataCheQC : An interactive, Shiny‐based app for quality control of pharmacometrics datasets
Dotan, O., Radivojevic, A., & Singh, R. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13017 · Cited by 2
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan
JPMA MIDD Task force, Sasaki, T., Katsube, T., Hayato, S., Yamaguchi, S., Tanaka, J., Yoshimatsu, H., Nakanishi, Y., Kitamura, A., Watase, H., et al. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09954-3 · Cited by 2
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement
Kadambi, A., Anderson, N., Visser, S. A. G., & Zierhut, M. L. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3620 · Cited by 2
Self-citation
Model-informed drug development of novel ROCK2 inhibitor TDI01: population pharmacokinetic study and simulation
Ji, X., & Cui, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1477607 · Cited by 2
Exposure-response modeling improves selection of radiation and radiosensitizer combinations
Cardilin, T., Almquist, J. O., Jirstrand, M., Zimmermann, A., Lignet, F., Bawab, S. E., & Gabrielsson, J. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09784-7 · Cited by 2
Use of statistical and pharmacokinetic–pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference
Kimko, H. H. C., Berry, S., O’Kelly, M., Mehrotra, N., Hutmacher, M. M., & Sethuraman, V. S. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1289956 · Cited by 2
Integrating dose estimation into a decision‐making framework for model‐based drug development
Dunyak, J., Mitchell, P., Hamrén, B., Helmlinger, G., Matcham, J., Stanski, D. R., & Al-Huniti, N. H. (2018) · Pharmaceutical Statistics · doi:10.1002/pst.1841 · Cited by 2
Self-citation
What “Impact” Do NLME Publications Have Outside Our Community?
Hennig, S., Fischer, J., & Kloft, C. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12501 · Cited by 2
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control
You, R., Weber, S., Bieth, B., & Vandemeulebroecke, M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2518 · Cited by 2
DosePredict: A Shiny Application for Generalized Pharmacokinetics‐Based Dose Predictions
Okour, M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1649 · Cited by 2
Application value of quantitative system pharmacology in drug discovery for traditional Chinese medicine
Meng, F., & Tao, X. (2020) · Journal of Medical Care Research and Review · doi:10.15520/mcrr.v3i9.113 · Cited by 1
Writing reports of modelling and simulation analysis: Our experience in the field of pharmacometrics
Moroso, V., Magnusson, M. O., & Jonsson, E. N. (2023) · Medical Writing · doi:10.56012/wmqy8556 · Cited by 1
Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer
Grišić, A., Hayes, S., Farrell, C. B., Kuroki, Y., Bertolino, M., Venkatakrishnan, K., & Girard, P. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3345 · Cited by 1
Population pharmacokinetic and exposure-response analysis to support a dosing regimen of CPX-351 (NS-87) in Japanese adult and pediatric patients with untreated high-risk acute myeloid leukemia
Imai, S., Kitada, A., Ogura, A., Akagi, M., Hasegawa, M., Vasilinin, G., Marier, J., Wang, Q., Ichikawa, T., & Kusano, K. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101038 · Cited by 1
The Role of Cross-Institutional and Interdisciplinary Collaboration in Defining and Executing a Quantitative Systems Pharmacology Strategy
Vicini, P., & van der Graaf, P. H. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_736 · Cited by 2
Model‐Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic Modeling
Eriksson, J., Sjögren, E., Gillon, J., Caplain, H., Goyal, V., Satam, V. S., Robinson, S., Ribeiro, I., & Chenel, M. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13309 · Cited by 1
Self-citation
Translational Model‐Informed Dose Selection for Iruplinalkib, a Selective Oral ALK / ROS1 Tyrosine Kinase Inhibitor
Yang, G., Wang, Y., Zhao, H., Zheng, Q., Wang, X., Jia, L., Xin, Q., Ma, C., Zhang, Y., Zheng, S., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70287 · Cited by 1
Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma
Shah, Z., Anderson, C. M., McCormick, K. D., Vallejo, C., Duncan, W., Hu, C., Zhou, J., Ratushny, A. V., & Kondic, A. G. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70145 · Cited by 1
Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain
Lou, Q., Zhou, H., Wang, Z., Cao, J., Tang, B., Zheng, Y., Wang, Y., Bai, X., van den Anker, J. N., Hao, G., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70143 · Cited by 1
Machine learning-based prediction model for teicoplanin plasma concentrations in adults with liver disease using real-world data
Jian, F., Chen, X., Wang, M., Guo, Z., Li, X., Jian, H., Ji, R., Liang, L., Yu, Z. Y., & Chen, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1703976 · Cited by 1
Intracellular Pharmacokinetics of Antidiabetic Drugs: A Focused Narrative Review of Subcellular Distribution (2015–2025)
Bafail, D. A. (2026) · Diseases · doi:10.3390/diseases14020062 · Cited by 1
From Classical PKPD to Model‐Informed Drug Development: Are “Digital Twins” a New Paradigm?
Houk, B. E. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70340 · Cited by 1
Best Practices in Physiologically Based Pharmacokinetic ( PBPK ) Modeling
Chenel, M., Dallmann, A., Ince, I., Meyer, M. C., Schlender, J., Teutonico, D., & Sjögren, E. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70295 · Cited by 1
Self-citation
Scaling Dose-Exposure-Response from Adults to Children
Rusten, I. S., Nordmark, A., Cole, S. M., Standing, J. F., Hietala, S. F., Zhao, W., Gigante, V., Hamberg, A., Pons, G., Garrido, M. J., et al. (2016) · Springer eBooks · doi:10.1007/978-3-319-43754-5_7 · Cited by 1
An Innovative Pharmacometric Approach for the Simultaneous Analysis of Frequency, Duration and Severity of Migraine Events
Pérez‐Pitarch, A., Gottipati, G., Uppoor, R. S., Mehta, M., & Sabarinath, S. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02907-8 · Cited by 1
A unified approach for evaluating the prediction of treatment effect across different types of endpoints
Qu, Y., Park, S. Y., Wu, Q., & Shen, W. (2021) · Pharmaceutical Statistics · doi:10.1002/pst.2149 · Cited by 1
Design of clinical development programs
Gibbs, M. A., Hamrén, B., Boulton, D. W., Tomkinson, H. K., & Iacona, R. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00034-3 · Cited by 1
Self-citation
Discovering the Knowledge in Unstructured Early Drug Development Data Using NLP and Advanced Analytics
Koneti, G., Das, S. S., Bahl, J., Ranjan, P., & Ramamurthi, N. (2022) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm55620.2022.9995435 · Cited by 1
Supporting Prospective Pregnancy Trials via Modeling and Simulation: Lessons From the Past and Recommendations for the Future
Cheung, S. Y. A., & Barrett, J. S. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2284 · Cited by 5
Self-citation
A tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials
Kulesh, V., Vasyutin, I., Volkova, A., Peskov, K. V., Kimko, H. H. C., Sokolov, V., & Alluri, R. V. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13082 · Cited by 1
Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer
Pan, M., Yan, L., Liu, Y., Xu, R., & Yang, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03715-4 · Cited by 1
Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity
Iwasa, T., Sachiko, Y. A. M. A., Hasegawa, C., Yoshitsugu, H., Nussbaum, J. C., Waskin, H. A., & Wrishko, R. E. (2024) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.55.3_99 · Cited by 1
Impact of Sampling Period on Population Pharmacokinetic Analysis of Antibiotics: Why do You Take Blood Samples Following the Fourth Dose?
Kim, S. W., Kim, D. J., Zang, D. Y., & Lee, D. H. (2020) · Pharmaceuticals · doi:10.3390/ph13090249 · Cited by 1
Model-informed drug development and discovery: an overview of current practices
Elmeliegy, M. A., & Ghobrial, O. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00014-3 · Cited by 2

Authors: Workgroup, E. M., Marshall, S., Burghaus, R., Cosson, V, Cheung, S., Chenel, M., DellaPasqua, O., Frey, N., Hamrén, B., Harnisch, L., Ivanow, F., Kerbusch, T., Lippert, J., Milligan, P., Rohou, S., Staab, A., Steimer, J., Tornøe, C., & Visser, S.
Affiliations: Pfizer (United Kingdom) (GB)
F. Hoffmann-La Roche AG (CH)
AstraZeneca (United Kingdom) (GB)
GlaxoSmithKline (United Kingdom) (GB)
Clinical Pharmacology Modelling & Simulation GlaxoSmithKline R&D Ltd Uxbridge UK
Janssen (United Kingdom) (GB)
MSD (Netherlands) (NL)
Pharmacometrics Pfizer Ltd Sandwich UK
Global Regulatory Affairs & Policy AstraZeneca Paris France
Novartis (Switzerland) (CH)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Quantitative Pharmacology & Pharmacometrics Merck & Co Kenilworth USA
Corresponding author: Marshall, SF
ORCID: Burghaus, R
Cosson, V
Cheung, SYA
Chenel, M
Frey, N
Hamrén, B
Harnisch, L
Kerbusch, T
Lippert, J
Venue: CPT: Pharmacometrics & Systems Pharmacology
Publisher: Wiley
Published: 2016-03
Volume: 5
Issue: 3
Pages: 93-122
ISSN: 2163-8306 (ISSN-L)
DOI: 10.1002/psp4.12049
PMC: PMC4809625
OpenAlex: W2181278642
Cited by: 373
References: 82
Citations by year: 2026: 26 · 2025: 44 · 2024: 37 · 2023: 36 · 2022: 32 · 2021: 51 · 2020: 38 · 2019: 40 · 2018: 33 · 2017: 22 · 2016: 12
FWCI: 22.58
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc
creativecommons.org/licenses/by-nc/4.0/ (vor, 13 d)
Locations: CPT Pharmacometrics & Systems Pharmacology (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: good practice recommendations, pharmacokinetic-pharmacodynamic modeling, R&D efficiency, regulatory guidelines, pharmaceutical industry
MeSH terms: Documentation, Technology, Pharmaceutical, Drug Design, Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks